Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference
February 18, 2026
Biotechnology
-
-
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Key IP Portfolio Advancements Align with Biotech Asset Trend
February 18, 2026
-
CEL-SCI Reports Fiscal First Quarter 2026 Results
February 18, 2026
-
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment
February 17, 2026
-
Devonian Advances Thykamine(TM) Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls
February 17, 2026
-
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 17, 2026
-
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board
February 17, 2026
-
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin
February 17, 2026
-
Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update
February 16, 2026
-
Iterum Therapeutics Provides Business Update
February 13, 2026
-
Moleculin Launches CEO Corner Platform to Share Strategic Insights
February 13, 2026
-
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
February 12, 2026
-
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases
February 12, 2026
-
Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway
February 12, 2026
-
CorMedix to Participate in Upcoming Investor Conferences
February 12, 2026
-
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
February 12, 2026